{
    "organizations": [],
    "uuid": "ebbf85a87289e087fc95a914ac50a35fa193bcdd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-atara-biotherapeutics-gets-fda-cle/brief-atara-biotherapeutics-gets-fda-clearance-to-proceed-with-multiple-sclerosis-study-idUSFWN1P50CE",
    "ord_in_thread": 0,
    "title": "BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - Atara Biotherapeutics Inc:\n* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS\n* ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019 ",
    "published": "2018-01-10T21:09:00.000+02:00",
    "crawled": "2018-01-11T12:44:36.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "atara",
        "biotherapeutics",
        "inc",
        "atara",
        "biotherapeutics",
        "announces",
        "fda",
        "clearance",
        "proceed",
        "enrollment",
        "site",
        "ongoing",
        "global",
        "phase",
        "clinical",
        "study",
        "evaluate",
        "ata188",
        "patient",
        "progressive",
        "multiple",
        "sclerosis",
        "atara",
        "biotherapeutics",
        "inc",
        "first",
        "result",
        "ata188",
        "phase",
        "study",
        "patient",
        "progressive",
        "m",
        "first",
        "half"
    ]
}